Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

Author:

Shah Neil P.1,Wallis Nicola2,Farber Harrison W.3,Mauro Michael J.4,Wolf Robert A.2,Mattei Daniele5,Guha Mausumee2,Rea Delphine6,Peacock Andrew7

Affiliation:

1. Division of Hematology/Oncology, San Francisco School of Medicine; University of California; San Francisco California

2. Department of Pulmonary Medicine, Critical Care and Allergy, Bristol-Myers Squibb; Princeton New Jersey

3. Boston University School of Medicine; Boston Massachusetts

4. Memorial Sloan Kettering Cancer Center; New York New York

5. Santa Croce Hospital; Cuneo Italy

6. Hôpital Saint-Louis; Paris France

7. Scottish Pulmonary Vascular Unit; Glasgow United Kingdom

Funder

BMS

Publisher

Wiley

Subject

Hematology

Reference34 articles.

1. Bristol-Myers Squibb Co 2014

2. Novartis Pharmaceutical Corp 2015

3. Novartis Pharmaceutical Corp. 2015

4. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient;Mattei;Bone Marrow Transplant,2009

5. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia;Rasheed;Leuk Res,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3